BioSpace News Archive

STOCKHOLM , Feb. 25, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate in development for the treatment of moderate to severe ulcerative colitis. The paper, published in the peer-reviewed Journal of Crohns and Colitis (JCC) , shows that t

Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to a R&D Day in Stockholm, Monday March 2, 2020, at 14:00 to 16:30 CET.

Feb. 25, 2020 09:00 UTC To develop and launch a kit dedicated to sample preparation for single-cell RNA-sequencing PARIS--( BUSINESS WIRE )-- Scipio bioscience, a Paris-based biotechnology company, developing a new generation of single-cell sequencing solutions, announces today that it has secured a €6.0 M Series A financing from an international syndicate led by M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck. The initial shareholders Se

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the financial results for the first half FY 2020 ended December 31, 2019. The webcast will begin at 4.30pm EST Wednesday, February 26; 8.30am AEDT Thursday, February 27, 2020

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that the Company’s Board of Directors has approved a second-quarter 2020 dividend of $0.16 per share.

CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced the appointment of Dr. Vaibhav Joshi to the newly created role of Chief Data Officer

Recognition honors those companies that take the long view with a purpose-based strategy and strive to create positive change throughout their global communities

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences:

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2019.

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced financial results for the fourth quarter and full-year ended December 31, 2019.